Volume 2 (2015): Issue 2

The road to cloning of factor VIII and the recombinant era

Open Access | | Creative Commons Attribution NonCommercial NoDerivatives
Edward Tuddenham

Abstract

Abstract

Use of recombinant clotting factor now represents the standard of care in haemophilia across the developed world. But the recombinant era would not have occurred without the isolation from plasma of factor VIII in sufficient quantities to allow characterisation and cloning. Much of this development work occurred at the Royal Free Hospital.

Article

View Full Article

References

  • 1. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50(1): 244-54.
  • 2. Owen WG, Wagner RH. Thromb Diath Haemorrh 1972; 27(3): 502-15.
  • 3. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312(5992): 337-42.
  • 4. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312(5992): 330-7.
  • 5. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312(5992): 326-30.
  • 6. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312(5992): 342-7.

PDF Download

Download PDF

Open in full-page viewer

Authors

  • Edward Tuddenham

    e.tuddenham@ucl.ac.uk
    Emeritus Professor of Haemophilia, University College, London UK